Evotec stock: EUR 2.71, down 0.73% premarket
Published on 11/20/2026 at 07:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec business and market setting
- Evotec combines drug research, advanced technology and AI-driven innovation with partnerships in pharmaceutical and biotechnology development.
- Its strategy includes drug discovery and development as well as biologics manufacturing through Just - Evotec Biologics.
Evotec stock traded at 2.71 euros on Lang & Schwarz at 07:47 CET on Friday, November 20, 2026, 0.73 percent below the Xetra close of Thursday, November 19.
Evotec develops drug candidates and drug-discovery technologies with pharmaceutical and biotechnology partners, according to Evotec.
European equities provide the broader market backdrop through current market reports.
Disclaimer...
en | DE0005664809 | EVOTEC SE | boerse | 70538853 | bgmi
